Neurocrine KINECT study fails to meet primary endpoints for cerebral palsy
Tweet Send to a Friend
Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced that its Phase 3 KINECT-DCP study of valbenazine in patients with dyskinetic cerebral palsy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
